Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?

31 Aug 2020

Abstract excerpt

Poly adenosine diphosphate-ribose polymerase inhibitors (PARPi) represent an effective therapeutic strategy for cancer patients harboring germline and somatic aberrations in DNA damage repair (DDR) genes. BRCA1/2 mutations occur at 1–7% across biliary tract cancers (BTCs), but a broader spectrum of DDR gene alterations is reported in 28.9–63.5% of newly diagnosed BTC patients. The open question is whether...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Colorectal and Anal Carcinomas

Source

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Identifiers

PMID: 32878011
DOI: 10.3390/medicines7090054

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PARP Inhibitors in Biliary Tract Cancer: A New Kid on the Block?PMID 32878011Read ↗

Investigational PARP inhibitors for the treatment of biliary tract cancer: spotlight on preclinical and clinical studiesSemantic proximity Read ↗

Targeting BRCA-mutant biliary tract cancer: Current evidence and future perspectives.Semantic proximity Read ↗

Phase II trial of niraparib for BRCA-mutated biliary tract, pancreatic and other gastrointestinal cancers: NIR-B.Semantic proximity Read ↗

Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving ParadigmSemantic proximity Read ↗

Understanding homologous recombination repair deficiency in biliary tract cancers: clinical implications and correlation with platinum sensitivity.Semantic proximity Read ↗

Molecular profile of BRCA-mutated biliary tract cancersSemantic proximity Read ↗

Current Status of Targeted Therapy for Biliary Tract Cancer in the Era of Precision MedicineSemantic proximity Read ↗

Targeting BRCA and DNA Damage Repair Genes in GI Cancers: Pathophysiology and Clinical PerspectivesSemantic proximity Read ↗

Therapeutic Potential of PARP Inhibitors in the Treatment of Gastrointestinal CancersSemantic proximity Read ↗

Emerging molecular target antagonists for the treatment of biliary tract cancer.Semantic proximity Read ↗

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract CancerSemantic proximity Read ↗

Genomic landscape of biliary tract cancer and corresponding targeted treatment strategiesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.